Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4149-4156

  Reichert, Maximilian ^a   Saur, Dieter ^a   Hamacher, Rainer ^a   Schmid, Roland M ^a   Schneider, Günter ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN A; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; F BOX PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CELL GROWTH PROCESSES; CHROMONES; E2F1 TRANSCRIPTION FACTOR; G1 PHASE; HCT116 CELLS; HELA CELLS; HUMANS; MORPHOLINES; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 34249335357     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4484     Document Type: Article

References (43)

1. Du W, Pogoriler J. Retinoblastoma family genes. Oncogene 2006;25:5190-200.
2. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
3. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41:2403-14.
4. Yamazaki K, Yajima T, Nagao T, et al. Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol Res Pract 2003;199:23-8.
5. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-81.
6. Einama T, Kagata V, Tsuda H, et al. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 2006;32:376-81.
7. Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIPI) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 2001;11:263-7.
8. Andreu EJ, Lledo E, Poch E, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005; 65:3264-72.
9. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
10. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003;89:2110-5.
11. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 2004;23:8571-80.
12. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res 2005;65:9164-8.
13. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
14. Perugini RA, McDade TP, Vittimberga FJ, Jr., Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000;90:39-44.
15. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002;1:989-97.
16. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
17. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003;89:391-7.
18. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol 37prime;-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004;28:353-8.
19. Shah SA, Potter MW, Hedeshian MH, Kim RD, Chari RS, Callery MP. PI-3′ kinase and NF-κB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg 2001;5:603-12; discussion 12-3.
20. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-κB/Rei activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
21. Schneider G, Oswald F, Wahl C, Greten FR, Adler G, Schmid RM. Cyclosporine inhibits growth through the activating transcription factor/cAMP-responsive element-binding protein binding site in the cyclin D1 promoter. J Biol Chem 2002;277:43599-607.
22. 1 to S-phase progression. EMBO J 2006;25:3801-12.
23. Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006;25: 2615-27.
24. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995;82:915-25.
25. Wirbelauer C, Sutterluty H, Blondel M, et al. The F-box protein Skp2 is a ubiquitylation target of a Cull-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent Fibroblasts. EMBO J 2000;19:5362-75.
26. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004; 428:190-3.
27. 1 by the anaphase-promoting complex. Nature 2004;428:194-8.
28. 1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med 2005; 202:157-68.
29. Wang IC, Chen YJ, Hughes D, et al. Forkbead box MI regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005;25: 10875-94.
30. Appleman LJ, Chernova I, Li L, Boussiotis VA. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation. Cell Cycle 2006;5:2123-9.
31. Huang YC, Hung WC. 1,25-Dihydroxyvitamin D(3) transcriptionally represses p45(Skp2) expression via the Sp1 sites in human prostate cancer cells. J Cell Physiol 2006;209:363-9.
32. Auld CA, Caccia CD, Morrison RF. Hormonal induction of adipogenesis induces Skp2 expression through PI3K and MAPK pathways. J Cell Biochem 2006;100:204-16.
33. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 1997;7:679-89.
34. Brennan P, Mehl AM, Jones M, Rowe M. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 2002;21:1263-71.
35. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999;1:14-9.
36. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995;92:12146-50.
37. Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A 1995;92:11264-8.
38. Shiftman D, Brooks EE, Brooks AR, Chan CS, Milner PG. Characterization of the human cyclin-dependent kinase 2 gene. Promoter analysis and gene structure. J Biol Chem 1996;271:12199-204.
39. Brooks AR, Shiffman D, Chan CS, Brooks EE, Milner PG. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem 1996;271:9090-9.
40. Iavarone A, Massague J. E2F and histone deacetylase mediate transforming growth factor β repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol 1999;19:916-22.
41. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12: 3499-511.
42. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-76.
43. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998;273:29864-72.